Rapport Therapeutics Balance Sheet
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rapport Therapeutics financial position
At the end of fiscal 2025, Rapport Therapeutics reported total assets of $512.4 million, up 62.7% from a year earlier against total liabilities of $27.8 million. Shareholders' equity stood at $484.7 million, or 94.6% of assets. The company held $52.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 26.17, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 52.65M | 56.80M | 70.17M |
| Short-Term Investments | 437.89M | 248.47M | 77.31M |
| Receivables | 0 | — | — |
| Total Current Assets | 498.56M | 309.80M | 150.87M |
| Property, Plant & Equipment | 2.98M | 3.53M | 1.92M |
| Total Assets | 512.43M | 314.93M | 155.42M |
| Accounts Payable | 4.19M | 1.95M | 2.50M |
| Total Current Liabilities | 19.05M | 8.77M | 8.80M |
| Total Liabilities | 27.78M | 9.51M | 14.48M |
| Shareholders' Equity | 484.65M | 305.43M | -25.63M |
| Retained Earnings | -235.23M | -123.75M | -45.44M |
| Net Cash (Debt) | 490.54M | 305.28M | 147.48M |
| Shares Outstanding | 47.77M | 36.58M | 4.17M |
This table shows 3 annual periods of Rapport Therapeutics's balance sheet, from FY 2025 back to FY 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a balance sheet?